José G. Pérez Ramos, PhD, MPH, Adriana Garriga-López, PhD, and Carlos E. Rodríguez-Díaz, PhD, MPH
Hurricane María, earthquakes, the COVID-19 pandemic, and relentless privatization and fragmentation of the health care system have led to very poor health outcomes.
AMA J Ethics. 2022;24(4):E305-312. doi:
10.1001/amajethics.2022.305.
Leah M. Marcotte, MD, Jeffrey Krimmel-Morrison, MD, and Joshua M. Liao, MD, MSc
Individuals can underperform in circumstances of shared accountability. In clinical settings, this is an unintended consequence of the health care sector’s complexity fragmentation.
AMA J Ethics. 2020;22(9):E802-807. doi:
10.1001/amajethics.2020.802.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.